Appendix Table 2.

Unadjusted outcomes at five years after transplantation in the subset of children, AYAs and older adults with AML in CR1 who received a myeloablative HCT

Outcome	1980-1988*		1989-1997*		1998-2005*		P-value
	N		N		N
Matched sibling donor HCT
Overall survival
Children	68	60 (48-72)%	120	58 (49-67)%	56	69 (55-81)%	0.41
Adolescent and young adults	262	49 (43-55)%	299	57 (52-63)%	96	52 (42-63)%	0.16
Older adults	23	35 (17-55)%	152	35 (28-43)%	146	47 (38-56)%	0.13
Leukemia-free survival
Children	67	61 (49-72)%	119	54 (44-63)%	55	65 (51-78)%	0.33
Adolescent and young adults	256	46 (40-52)%	297	53 (47-58)%	95	51 (41-61)%	0.32
Older adults	22	32 (14-52)%	150	35 (28-43)%	144	46 (37-55)%	0.16
Relapse
Children	67	15 (7-24)%	119	38 (30-47)%	55	21 (11-33)%	<0.01
Adolescent and young adults	256	17 (13-22)%	297	20 (16-25)%	95	28 (20-38)%	0.09
Older adults	22	14 (3-31)%	150	22 (16-29)%	144	25 (18-32)%	0.40
Treatment related mortality
Children	67	24 (15-35)%	119	8 (4-14)%	55	14 (6-26)%	0.02
Adolescent and young adults	256	37 (31-43)%	297	27 (22-32)%	95	20 (13-29)%	<0.01
Older adults	22	55 (34-74)%	150	43 (35-51)%	144	29 (22-37)%	0.02
Unrelated donor HCT
Overall survival
Children		-	44	36 (23-51)%	91	34 (24-45)%	0.81
Adolescent and young adults		-	93	22 (15-31)%	235	41 (34-48)%	<0.01
Older adults		-	45	22 (11-35)%	261	34 (28-41)%	0.09
Leukemia-free survival
Children		-	44	32 (19-46)%	91	35 (25-45)%	0.71
Adolescent and young adults		-	92	22 (14-31)%	231	40 (33-46)%	<0.01
Older adults		-	45	22 (11-35)%	257	34 (28-41)%	0.09
Relapse
Children		-	44	30 (17-44)%	91	35 (25-45)%	0.53
Adolescent and young adults		-	92	12 (6-19)%	231	24 (19-30)%	<0.01
Older adults		-	45	16 (7-27)%	257	27 (21-33)%	0.07
Treatment related mortality
Children		-	44	39 (25-53)%	91	30 (21-40)%	0.33
Adolescent and young adults		-	92	66 (56-76)%	231	36 (30-43)%	<0.01
Older adults		-	45	62 (48-76)%	257	39 (33-45)%	<0.01

^*Probability and 95% confidence intervals